Bioloom: high-resolution 3d (bio)printing platform
BioLoom is a configurable robotic platform for multi-material 3D bioprinting, designed to enable next-generation in vitro tissue and organoid models with high reproducibility and architectural control.
What it enables (for pharma R&D)
- Reproducible fabrication of 3D in vitro tissue models and organoids
- Precise control over microarchitecture, cell distribution, and material composition Key capabilities
- True multi-material bioprinting (hydrogels, bioinks, polymers)
- Hybrid fabrication: combine extrusion, electrospinning, electrowriting in one build
- Micron-scale structural control for physiologically relevant architectures
- Parallel tool operation for higher throughput and repeatability Unique technology (BioLoom differentiation)
- Dual-turret system (up to 10 tools) enabling rapid tool switching and hybrid builds
- GMP-compliant controlled environment (temperature, humidity, HEPA + UV sterilization) for sensitive biological materials
- Integrated computer vision monitoring for real-time quality control and defect detection
- Seamless CAD-to-fabrication pipeline via Loominus (design → simulation → print) Why it matters for in vitro models
- Improves reproducibility vs. manual organoid culture
- Enables structured, biomimetic environments (beyond spheroids)
- Supports development of next-gen disease models with spatial fidelity Applications
- Resorbable architected biomaterial implants
- 3D tumor models and microenvironment engineering
- Drug screening & toxicity testing platforms
- Organoid engineering with defined architecture
- Advanced tissue models for preclinical research Partnership opportunities
- Co-development of application-specific in vitro models
- Validation in pharma R&D pipelines I- Integration into high-throughput screening workflows
About Biological Lattice Industries Corp.
Biological Lattice Industries Corp. (BLI) is a deep-tech startup that specializes in biofabrication and life sciences research and development. The company has developed an integrated, end-to-end platform that combines hardware and software to automate and streamline laboratory workflows. Its flagship offering includes Loominus Studio, a no-code, unified software platform that enables researchers to design, manage, and automate complex biofabrication workflows. This is complemented by the BioLoom, a multi-tool, extrusion-based 3D bioprinter that features active environmental control to ensure high-resolution, reproducible printing of biomaterials and devices. By unifying these tools, BLI aims to replace fragmented manual processes with an intelligent, automated system that bridges the gap between digital design and physical fabrication.
This technology is designed to assist life sciences researchers in accelerating the development of advanced medical and biological applications, such as 3D cell culture systems for human biology emulation, drug delivery platforms, and resorbable medical devices. By providing a scalable, GMP-compliant solution that emphasizes reproducibility and precision, BLI enables laboratories to improve operational efficiency and fast-track the commercialization of their research. The company, founded in 2021 with roots at MIT, operates with a global presence, maintaining its headquarters in Boston and research operations at the Lefkippos Technological Park in Greece. Supported by venture capital, the company aims to establish its platform as an industry standard for biofabrication labs worldwide.
Inquire about this partnering listing
Looking for
Industry applications
delivered to your inbox.